Core Viewpoint - The stock of Insilico Medicine (03696) has risen over 4%, reaching a new high of 72.4 HKD, driven by significant milestone payments from its collaboration with Menarini Group for the MEN2501 project [1] Group 1: Financial Performance - Insilico Medicine received a milestone payment of 39 million HKD from Menarini Group after the first patient was dosed in the Phase I clinical trial of MEN2501 [1] - The company has achieved a total of 3 business development (BD) collaborations since 2026, with upfront payments totaling 42 million USD, including recent research milestone payments [1] - The total amount from these collaborations has reached 1.074 billion USD, indicating strong commercial validation of the company's value [1] Group 2: Product Development - MEN2501 is a highly differentiated KIF18A inhibitor designed and optimized by Insilico's generative AI engine, aimed at treating chromosomal instability solid tumors [1] - The core pipeline ISM001-055 is the only fully AI-developed drug to have obtained Phase II clinical data globally, with potential to become a disruptive therapy [1] - The company is expected to achieve more BD collaborations in 2026, which could act as a direct catalyst for stock price appreciation [1]
英矽智能再涨超4%破顶 开年至今已达成3项BD合作 机构看好公司长期发展